The rise of artificial intelligence (A.I.) in the pharmaceutical industry signifies a transformative period, placing unprecedented power in the hands of tech-driven drug discovery and igniting debates about innovation, control, and patient safety. Subject to regulatory scrutiny, the FDA has
In the world of modern medicine, finding innovative, safer, and more effective treatments for cancer remains a relentless pursuit. Researchers from the University of Nottingham have turned their attention to an unassuming yet potent ally in this fight—the parasitic fungus Cordyceps militaris. S
Cancer research has entered a new era with the advent of patient-derived organoids (PDOs). These sophisticated three-dimensional (3D) models, grown from patient cells, have revolutionized our understanding of tumors and their microenvironments. By mimicking the complexity of human tumors, PDOs have
AstraZeneca has recently submitted a Biologics License Application (BLA) to the FDA for datopotamab deruxtecan (Dato-DXd), targeting accelerated approval for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) that possess EGFR mutations. This submission is a significant
Comprehensive Genomic Profiling (CGP) is revolutionizing cancer treatment by enabling early detection and personalized therapy. A recent study published in the Journal of Clinical Oncology - Oncology Practice (JCO-OP) highlights the significant benefits of early CGP testing in improving clinical
The collaboration between ViaNautis Bio (ViaNautis) and Eli Lilly and Company (Lilly) marks a significant advancement in the field of genetic medicine. This partnership aims to leverage ViaNautis' cutting-edge polyNaut technology to develop precision genetic medicines that can deliver genetic
